Exploring Biomarkers to Predict Thrombogenic Risk in Pregnancy

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Thrombosis Research

Background:

• Pregnancy and postpartum states inherently increase the risk of thrombosis.
• Effective monitoring of coagulation markers is crucial for preventing adverse maternal and fetal thrombotic events.
• Fibrinogen/fibrin degradation products (FDPs) are primary coagulation markers used in pregnancy.

Purpose of the Study:

• To investigate protein C and S, antiphospholipid antibodies (APLs), and beta-2-glycoprotein 1 levels.
• To identify differences between normal third-trimester pregnancies and those complicated by deep vein thrombosis (DVT).

Main Methods:

• Assessed levels of proteins C and S, APLs, and beta-2-glycoprotein 1 (apolipoprotein H).
• Compared marker levels between healthy pregnant women and those with DVT in late pregnancy.
• Correlated protein C levels with gestational weeks.

Main Results:

• Protein C levels showed a significant correlation with gestational weeks.
• Statistically significant differences in FDP, protein S, and APL levels were observed between healthy and DVT groups.
• Women with DVT exhibited higher FDP levels but lower APL and protein S values compared to controls.

Conclusions:

• Protein C and S levels demonstrate a significant prothrombotic correlation.
• Variations in protein C and S levels can serve as valuable markers for assessing thrombotic risk in late pregnancy.
• This study highlights potential biomarkers for DVT risk stratification during the third trimester.